These findings provide evidence that treatment with HMGB1 inhibitors represents a novel and effective approach toward the rebalancing of disease-associated and disease-protective glial cells to combat APOE4-driven pathogenesis of AD. Here, HMGB1 is linked to Alzheimer disease.